KR102604876B1 - Mcl-1 억제제의 합성 - Google Patents
Mcl-1 억제제의 합성 Download PDFInfo
- Publication number
- KR102604876B1 KR102604876B1 KR1020197031979A KR20197031979A KR102604876B1 KR 102604876 B1 KR102604876 B1 KR 102604876B1 KR 1020197031979 A KR1020197031979 A KR 1020197031979A KR 20197031979 A KR20197031979 A KR 20197031979A KR 102604876 B1 KR102604876 B1 KR 102604876B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- mol
- dimethyl
- solvent
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479493P | 2017-03-31 | 2017-03-31 | |
| US62/479,493 | 2017-03-31 | ||
| PCT/EP2018/058056 WO2018178227A1 (en) | 2017-03-31 | 2018-03-29 | Synthesis of mcl-1 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190136039A KR20190136039A (ko) | 2019-12-09 |
| KR102604876B1 true KR102604876B1 (ko) | 2023-11-22 |
Family
ID=61827753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197031979A Active KR102604876B1 (ko) | 2017-03-31 | 2018-03-29 | Mcl-1 억제제의 합성 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11149024B2 (enExample) |
| EP (1) | EP3601230B1 (enExample) |
| JP (1) | JP7032428B2 (enExample) |
| KR (1) | KR102604876B1 (enExample) |
| CN (1) | CN110536884B (enExample) |
| AR (1) | AR111304A1 (enExample) |
| AU (1) | AU2018244180B2 (enExample) |
| CA (1) | CA3056712A1 (enExample) |
| CO (1) | CO2019010035A2 (enExample) |
| EA (1) | EA038226B1 (enExample) |
| ES (1) | ES2909751T3 (enExample) |
| IL (1) | IL269410B2 (enExample) |
| MX (1) | MX387814B (enExample) |
| TW (1) | TWI781996B (enExample) |
| WO (1) | WO2018178227A1 (enExample) |
| ZA (1) | ZA201905645B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691989B2 (en) | 2018-11-22 | 2023-07-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as Mcl-1 inhibitors |
| US12319703B2 (en) | 2019-01-23 | 2025-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrazoles as Mcl-1 inhibitors |
| KR20220024694A (ko) | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| WO2021005043A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021099579A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as mcl-1 inhibitors |
| MX2022006180A (es) | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |
| JP2023514364A (ja) | 2020-02-21 | 2023-04-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状インドール誘導体 |
| EP4157852A1 (en) | 2020-05-29 | 2023-04-05 | JANSSEN Pharmaceutica NV | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| MX2022015998A (es) * | 2020-06-19 | 2023-04-12 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1. |
| WO2021255257A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CA3184877A1 (en) | 2020-07-08 | 2022-01-13 | Benoit Christian Albert Ghislain De Boeck | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| JP2023553719A (ja) | 2020-12-17 | 2023-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体 |
| JP2024506648A (ja) | 2021-02-12 | 2024-02-14 | ヤンセン ファーマシューティカ エヌ．ベー． | がんの治療のためのｍｃｌ－１阻害剤としての大環状１，３－架橋６－クロロ－７－ピラゾール－４－イル－１ｈ－インドール－２－カルボキシレート及び６－クロロ－７－ピリミジン－５－イル－１ｈ－インドール－２－カルボキシレート誘導体 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106731A1 (en) | 2014-10-17 | 2016-04-21 | Vanderbilt University | Tricyclic indole mcl-1 inhibitors and uses thereof |
| WO2017182625A1 (en) | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915811A1 (en) * | 2014-03-04 | 2015-09-09 | Centre Régional de Lutte contre le Cancer - Centre François Baclesse | MCL-1 modulating compounds for cancer treatment |
| CN105061315B (zh) * | 2015-08-06 | 2017-10-24 | 大连理工大学 | 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用 |
| CN106478606B (zh) * | 2016-09-21 | 2019-05-10 | 沈阳药科大学 | N-取代吲哚类衍生物及其应用 |
-
2018
- 2018-03-26 TW TW107110205A patent/TWI781996B/zh active
- 2018-03-28 AR ARP180100757A patent/AR111304A1/es unknown
- 2018-03-29 MX MX2019011468A patent/MX387814B/es unknown
- 2018-03-29 EP EP18714249.2A patent/EP3601230B1/en active Active
- 2018-03-29 JP JP2019552891A patent/JP7032428B2/ja active Active
- 2018-03-29 CA CA3056712A patent/CA3056712A1/en active Pending
- 2018-03-29 AU AU2018244180A patent/AU2018244180B2/en active Active
- 2018-03-29 WO PCT/EP2018/058056 patent/WO2018178227A1/en not_active Ceased
- 2018-03-29 US US16/497,919 patent/US11149024B2/en active Active
- 2018-03-29 KR KR1020197031979A patent/KR102604876B1/ko active Active
- 2018-03-29 ES ES18714249T patent/ES2909751T3/es active Active
- 2018-03-29 EA EA201992235A patent/EA038226B1/ru unknown
- 2018-03-29 CN CN201880021146.0A patent/CN110536884B/zh active Active
-
2019
- 2019-08-27 ZA ZA2019/05645A patent/ZA201905645B/en unknown
- 2019-09-16 CO CONC2019/0010035A patent/CO2019010035A2/es unknown
- 2019-09-17 IL IL269410A patent/IL269410B2/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106731A1 (en) | 2014-10-17 | 2016-04-21 | Vanderbilt University | Tricyclic indole mcl-1 inhibitors and uses thereof |
| WO2017182625A1 (en) | 2016-04-22 | 2017-10-26 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019019686A2 (pt) | 2020-04-14 |
| CA3056712A1 (en) | 2018-10-04 |
| CO2019010035A2 (es) | 2019-09-30 |
| US20210122735A1 (en) | 2021-04-29 |
| IL269410A (en) | 2019-11-28 |
| ZA201905645B (en) | 2020-05-27 |
| EA201992235A1 (ru) | 2020-02-10 |
| MX2019011468A (es) | 2019-11-01 |
| AU2018244180A1 (en) | 2019-11-07 |
| TW201902868A (zh) | 2019-01-16 |
| KR20190136039A (ko) | 2019-12-09 |
| CN110536884A (zh) | 2019-12-03 |
| TWI781996B (zh) | 2022-11-01 |
| AR111304A1 (es) | 2019-06-26 |
| JP7032428B2 (ja) | 2022-03-08 |
| EP3601230A1 (en) | 2020-02-05 |
| EP3601230B1 (en) | 2022-01-26 |
| EA038226B1 (ru) | 2021-07-27 |
| JP2020515557A (ja) | 2020-05-28 |
| IL269410B2 (en) | 2023-03-01 |
| CN110536884B (zh) | 2023-05-02 |
| WO2018178227A1 (en) | 2018-10-04 |
| ES2909751T3 (es) | 2022-05-10 |
| MX387814B (es) | 2025-03-04 |
| US11149024B2 (en) | 2021-10-19 |
| AU2018244180B2 (en) | 2021-03-04 |
| IL269410B (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102604876B1 (ko) | Mcl-1 억제제의 합성 | |
| KR101593253B1 (ko) | 페닐 및 벤조디옥시닐 치환 인다졸 유도체 | |
| EP3567043B1 (en) | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer | |
| KR20230096973A (ko) | Jak 저해제를 제조하기 위한 방법 및 중간체 | |
| WO2022089604A1 (en) | New crystalline forms of a kras g12c inhibitor compound | |
| CN107163028A (zh) | 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用 | |
| JP2020535193A (ja) | 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス | |
| KR101357392B1 (ko) | 합성 중간체로서의 티아졸릴-피라졸로피리미딘 화합물 및 관련 합성 방법 | |
| CN110511214A (zh) | 二胺基取代芳杂环类化合物及其制备方法和应用 | |
| JP2025518342A (ja) | ベンゾ［ｃ］クロマン化合物の多形、その製造方法、及びその使用 | |
| HK40022816B (en) | Synthesis of mcl-1 inhibitor | |
| HK40022816A (en) | Synthesis of mcl-1 inhibitor | |
| JP2025518345A (ja) | ベンゾ［ｃ］クロマン化合物の薬学的に許容される塩、ならびに薬学的に許容される塩の多形及び使用 | |
| BR112019019686B1 (pt) | Compostos selecionados para síntese de inibidor de mcl-1 | |
| HK40013365A (en) | Synthesis of mcl-1 inhibitor | |
| HK40013365B (en) | Synthesis of mcl-1 inhibitor | |
| CN119156384B (en) | Polymorphic forms of benzo [ c ] chroman compounds, methods of making and uses thereof | |
| WO2021213111A1 (zh) | Snail抑制剂及其衍生物，制备方法、药物组合物和应用 | |
| KR20200092945A (ko) | 레날리도마이드의 결정형 | |
| CN108640930B (zh) | 一种对氯取代含吡唑结构的螺[吲哚嗪-异噁唑啉]衍生物及其制备方法与应用 | |
| US8242264B2 (en) | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | |
| CN119528929A (zh) | 鬼臼毒素三氮唑醚衍生物及其制备方法和应用 | |
| CN118702675A (zh) | 一类哌嗪酰胺衍生物及其制备方法和应用 | |
| CN120441575A (zh) | 一种西他列汀中间体的制备方法 | |
| CN119431319A (zh) | 环戊基并吡啶衍生物的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |